EMD-28596

Single-particle
3.5 Å
EMD-28596 Deposition: 17/10/2022
Map released: 02/11/2022
Last modified: 19/06/2024
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-28596

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-8etr summary report (pdf.gz) Map-8etr FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

CryoEM Structure of NLRP3 NACHT domain in complex with G2394

EMD-28596

Single-particle
3.5 Å
EMD-28596 Deposition: 17/10/2022
Map released: 02/11/2022
Last modified: 19/06/2024
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: NLRP3 NACHT domain
Fitted models: 8etr

Deposition Authors: Murray JM, Johnson MC
Overcoming Preclinical Safety Obstacles to Discover ( S )- N -((1,2,3,5,6,7-Hexahydro- s -indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5 H -pyrazolo[5,1- b ][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.
PUBMED: 36279149
DOI: doi:10.1021/acs.jmedchem.2c01250
ISSN: 0022-2623
ASTM: JMCMAR
Grant Support: